The role of CXCR4 in Multiple Myeloma: Cells’ Journey from Bone Marrow to Beyond
Publication date: Available online 16 July 2019Source: Journal of Bone OncologyAuthor(s): Tomalika Rahmat UllahAbstractCXCR4 is a pleiotropic chemokine receptor which acts through its ligand CXCL12 to regulate diverse physiological processes. CXCR4/CXCL12 axis plays a pivotal role in proliferation, invasion, dissemination and drug resistance in multiple myeloma (MM). Apart from its role in homing, CXCR4 also affects MM cell mobilization and egression out of the bone marrow (BM) which is correlated with distant organ metastasis. Aberrant CXCR4 expression pattern is associated with osteoclastogenesis and tumor growth in MM t...
Source: Journal of Bone Oncology - July 17, 2019 Category: Cancer & Oncology Source Type: research

Is there a role for Denosumab and bone health for prostate and breast cancer patients undergoing endocrine therapy? A systematic review and a meta-analysis of randomized trials
In conclusion, Denosumab administration can be considered effective and safe in the prevention and management of the above mentioned adverse events related to hormonal therapies designed for breast and prostate tumors. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - July 17, 2019 Category: Cancer & Oncology Source Type: research

The dual mechanisms of 99mTc-MIBI scintigraphy were used to predict and evaluate neoadjuvant chemotherapy for osteosarcoma
Publication date: Available online 9 July 2019Source: Journal of Bone OncologyAuthor(s): Caixia Wu, Qian Wang, Yuan LiAbstractPurposeTo investigate the feasibility of applying the dual imaging mechanisms of 99mTc-MIBI scintigraphy in predicting and evaluating the response to neoadjuvant chemotherapy in patients with osteosarcoma.Materials and methodThirty patients with osteosarcoma who underwent both pre-and post-chemotherapy 99mTc-MIBI scintigraphy were enrolled in the study. T/B value, tumor washout rate (WR) before chemotherapy and alteration rate (AR) of tumor uptake after chemotherapy was evaluated respectively. Based...
Source: Journal of Bone Oncology - July 11, 2019 Category: Cancer & Oncology Source Type: research

The Homogeneous And Heterogeneous Risk Factors For Occurrence And Prognosis In Lung Cancer Patients With Bone Metastasis
ConclusionThe morbidity of bone metastasis in lung cancer patients is dismal, with a rate of 25.9%. The findings of this study estimate the homogeneous and heterogeneous risk factors for the occurrence and prognosis of bone metastasis in lung cancer patients, which may provide clinical guidelines for physicians.Graphical abstract (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - July 10, 2019 Category: Cancer & Oncology Source Type: research

Changing Landscape of Optical Imaging in Skeletal Metastases
Publication date: Available online 27 June 2019Source: Journal of Bone OncologyAuthor(s): Nicholas Cho, Monica ShokeenAbstractOptical imaging is an emerging strategy for in vitro and in vivo visualization of the molecular mechanisms of cancer over time. An increasing number of optical imaging contrast agents and techniques have been developed in recent years specifically for bone research and skeletal metastases. Visualizing molecular processes in relation to bone remodeling in metastasized cancers provides valuable information for understanding disease mechanisms and monitoring expression of primary molecular targets and ...
Source: Journal of Bone Oncology - June 28, 2019 Category: Cancer & Oncology Source Type: research

Chondroblastoma of bone in extremities. - A single centre study of 177 cases
ConclusionsChondroblastoma is a rare benign to intermediate grade bone tumour with a potential to metastasise. Femoral head chondroblastoma is rare, presenting 4.5% of all chondroblastoma cases. Around 50% of the chondroblastoma in femoral head. occur in patients with open growth plates. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - June 28, 2019 Category: Cancer & Oncology Source Type: research

Application of nomograms to predict overall and cancer-specific survival in patients with chordoma
Publication date: Available online 24 June 2019Source: Journal of Bone OncologyAuthor(s): Weipeng Zheng, Yuanping Huang, Tianwang Guan, Songfang Lu, Liquan Yao, Senrui Wu, Haoyi Chen, Ning Wang, YingJie Liang, Wende Xiao, Xin Jiang, Shifeng WenAbstractBackground: The survival prediction of patients with chordoma is difficult to make due to the rarity of this oncologic disease. Our objective was to apply a nomogram to predict survival outcomes in individuals with chordoma of the skull base, vertebral column, and pelvis.Methods: A total of 558 patients with chordoma between 1973 and 2014 were collected from the Surveillance,...
Source: Journal of Bone Oncology - June 25, 2019 Category: Cancer & Oncology Source Type: research

Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation
This study demonstrates the capacity of the PARP inhibitor Olaparib to radiosensitize mutated chondrosarcoma cells to conventional photon irradiation and proton and carbon ion irradiation.Graphical abstract (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - June 20, 2019 Category: Cancer & Oncology Source Type: research

The bone metastasis niche in breast cancer-potential overlap with the haematopoietic stem cell niche in vivo
Conclusion: Our data provide evidence that homing of breast cancer cells is independent of their ER status and that the breast cancer bone metastasis niche is located within the trabecular region of bone, an area rich in osteoblasts and microvessels. The increased number of breast cancer cells homing to bone after mobilisation of HSCs suggests that the HSC and the bone metastasis niche overlap. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - June 14, 2019 Category: Cancer & Oncology Source Type: research

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
In this study, we established the osteosarcoma mouse tumor model resistant to anti-PD1 mAb that harbored PD1hi T cells. Furthermore, flow cytometry analysis of tumor infiltrating leukocytes after treatment was used as a screening platform to identify agents that could re-sensitize T cells to anti-PD1 mAb. Results showed that anti-CD40 mAb treatment converted PD1hi T cells to PD1lo T cells, reversing phenotypic T cell exhaustion and sensitizing anti-PD1 refractory tumors to respond to anti-PD1 mAb. Results also showed that intratumor Treg presented with a less activated and attenuated suppressive phenotype after anti-CD40 m...
Source: Journal of Bone Oncology - June 13, 2019 Category: Cancer & Oncology Source Type: research

The bone metastasis niche in breast cancer–potential overlap with the haematopoietic stem cell niche in vivo
Conclusion: Our data provide evidence that homing of breast cancer cells is independent of their ER status and that the breast cancer bone metastasis niche is located within the trabecular region of bone, an area rich in osteoblasts and microvessels. The increased number of breast cancer cells homing to bone after mobilisation of HSCs suggests that the HSC and the bone metastasis niche overlap. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - June 7, 2019 Category: Cancer & Oncology Source Type: research

Unplanned admissions for patients with myeloma in the UK: low frequency but high costs
ConclusionsMM is associated with a significant number of hospital admissions and NHS costs. The majority of the hospital admissions are elective, but the highest burden in terms of costs relates to unplanned admissions, with numbers increasing over time. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - June 7, 2019 Category: Cancer & Oncology Source Type: research

Have the difficulties and complications of surgical treatment for chondroblastoma of the adjoining knee joint been overestimated?
ConclusionsIntraregional aggressive curettage, phenolization, and allogeneic bone grafting are effective for treatment of chondroblastoma of the adjoining knee joint. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - May 14, 2019 Category: Cancer & Oncology Source Type: research

MiR-193a regulates chemoresistance of human osteosarcoma cells via repression of IRS2
Publication date: Available online 11 May 2019Source: Journal of Bone OncologyAuthor(s): Haiyan Wang, Fangfang Zhao, Shanbao Cai, Youguang PuAbstractChemoresistance prevents curative potential of chemotherapy in most cases. MicroRNAs (miRNAs) are key players in regulating chemoresistance in osteosarcoma, which is the most common primary bone cancer. Bisulfite sequencing and quantitative real time PCR analyses showed that miR-193a expression is downregulated by DNA hypermethylation at its promoter region in a chemoresistant cell line, SJSA-1, compared to a chemosensitive cell line G-292. Introductio...
Source: Journal of Bone Oncology - May 11, 2019 Category: Cancer & Oncology Source Type: research

CXCR4 in human osteosarcoma malignant progression. The response of osteosarcoma cell lines to the fully human CXCR4 antibody MDX1338
Publication date: Available online 8 May 2019Source: Journal of Bone OncologyAuthor(s): Serena Pollino, Emanuela Palmerini, Barbara Dozza, Elisa Bientinesi, Martina Piccinni-Leopardi, Enrico Lucarelli, Alberto Righi, Maria Serena Benassi, Laura PazzagliaABSTRACTOsteosarcoma (OS) is the most frequent primary malignant tumour of bone and metastases occur in 30% of cases, the 5-year survival rate is 25-30%.Although pre- and post-operative chemotherapy has improved prognosis in osteosarcoma (OS), high toxicity and natural and acquired drug–resistance are the first cause of treatment failure. The identification of new pre...
Source: Journal of Bone Oncology - May 8, 2019 Category: Cancer & Oncology Source Type: research

Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model
Publication date: Available online 29 April 2019Source: Journal of Bone OncologyAuthor(s): Zhang Kun, Gao Xin, Wang Tao, Zhao Chenglong, Wang Dongsheng, Tang Liang, Liu Tielong, Xiao JianruAbstractEpidermal growth factor-like repeats and discoidin I like domain 3 (EDIL3) is an integrin ligand which is implicated in bone metabolism and bone marrow myelopoiesis. Recently, myeloid derived suppressor cells (MDSCs) as osteoclast progenitor have been demonstrated in several kinds of cancers including breast cancer. In this paper we explored the association between tumor derived EDIL3 and MDSCs in a murine breast cancer model. Kn...
Source: Journal of Bone Oncology - April 30, 2019 Category: Cancer & Oncology Source Type: research

RETRACTED: Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
Publication date: April 2019Source: Journal of Bone Oncology, Volume 15Author(s): Shenglong Li, Peng Chen, Qiankun YangAbstractBackgroundAlthough denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven.ObjectivesTo compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with surgically unsalvageable giant cell tumor of bone.MethodsA total of 250 patients with surgically unsalvageable giant cell tumor of bone were included in this randomized clinical trial. Patients received either subcutaneous denosumab (DB group; 120 mg per 4 we...
Source: Journal of Bone Oncology - April 13, 2019 Category: Cancer & Oncology Source Type: research

Pelvic reconstruction following resection of tumour involving the whole ilium and acetabulum
ConclusionsThe procedure of femoral head autograft plus hemipelvic prosthesis was an effective method to reconstruct the defect following the whole ileum and the acetabulum resection; the functional outcomes were satisfactory, and it had an acceptable complication rate. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - April 10, 2019 Category: Cancer & Oncology Source Type: research

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
Publication date: Available online 4 April 2019Source: Journal of Bone OncologyAuthor(s): Andy Göbel, Jan D. Kuhlmann, Theresa Link, Pauline Wimberger, Cornelia Link-Rachner, Stefanie Thiele, Stefania Dell'Endice, Giulia Furesi, Dorit Breining, Martina Rauner, Lorenz C. Hofbauer, Tilman D. RachnerAbstractBackgroundSemaphorin 4D (Sema4D) is a glycoprotein that inhibits bone formation and has been associated with cancer progression and the occurrence of bone metastases. Recently, Sema4D expression has been linked to estrogen signaling in breast cancer. Endocrine therapies like tamoxifen and aromatase inhibitors (AI) are...
Source: Journal of Bone Oncology - April 6, 2019 Category: Cancer & Oncology Source Type: research

Role of autophagy in osteosarcoma
Publication date: Available online 3 April 2019Source: Journal of Bone OncologyAuthor(s): Olivier Camuzard, Sabine Santucci-Darmanin, Georges F. Carle, Valérie Pierrefite-CarleAbstractOsteosarcoma (OS) is the most common primary bone tumour in children and adolescents. It is a highly aggressive tumor with a tendency to spread to the lungs, which are the most common site of metastasis. Advanced osteosarcoma patients with metastasis share a poor prognosis. Despite the use of chemotherapy to treat OS, the 5-year overall survival rate for patients has remained unchanged at 65-70% for the past 20 years. In addition, the ...
Source: Journal of Bone Oncology - April 4, 2019 Category: Cancer & Oncology Source Type: research

Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma
Publication date: Available online 3 April 2019Source: Journal of Bone OncologyAuthor(s): Minghui Li, Yajie Lu, Zuoyao Long, Mengyang Li, Jing Kong, Guojing Chen, Zhen WangAbstractOsteosarcoma is the most common form of primary malignant bone tumor, with metastasis playing an essential role in determining a patient's prospects for survival. It is essential that new and better molecular targets that respond effectively to therapies and are predictive of the risk of tumor metastasis are identified. We have therefore undertaken the present prospective study to ascertain the clinical significance of circulating tumor cells (CT...
Source: Journal of Bone Oncology - April 4, 2019 Category: Cancer & Oncology Source Type: research

Pelvic reconstruction following resection of tumor involving the whole ilium and acetabulum
ConclusionsThe procedure of femoral head autograft plus hemipelvic prosthesis was an effective method to reconstruct the defect following the whole ileum and the acetabulum resection; the functional outcomes were satisfactory, and it had an acceptable complication rate. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - March 30, 2019 Category: Cancer & Oncology Source Type: research

Bone tumours of the clavicle: Histopathological, anatomical and epidemiological analysis of 113 cases
Publication date: June 2019Source: Journal of Bone Oncology, Volume 16Author(s): Matthias H. Priemel, Norbert Stiel, Jozef Zustin, Andreas M. Luebke, Carsten Schlickewei, Alexander S. SpiroAbstractBackroundThis retrospective study aimed to determine the frequency of bone tumours of the clavicle and their histopathological, anatomical and epidemiological characteristics in a large case series.MethodsThe records of 327 lesions of the clavicle collected from 1976 to 2018 in our bone tumour registry and institute of pathology were reviewed. Following data were evaluated: age, gender, side, radiological assessment, tumour locat...
Source: Journal of Bone Oncology - March 30, 2019 Category: Cancer & Oncology Source Type: research

Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer
Publication date: Available online 7 November 2018Source: Journal of Bone OncologyAuthor(s): Xinge Shi, Xiqing Li, Hongqiang Wang, Zhenghong Yu, Yu Zhu, Yanzheng GaoABSTRACTImpressive responses have been observed in patients with cancer treated with checkpoint inhibitory anti-programmed cell death-1 (PD-1) or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies through disinhibiting the immune system. However, tumors possess complex immunosuppressive tumor microenvironment to present therapeutic obstacles and the response rates to immune checkpoint inhibition remain low. One significant barrier to the effic...
Source: Journal of Bone Oncology - March 20, 2019 Category: Cancer & Oncology Source Type: research

Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
Publication date: Available online 19 March 2019Source: Journal of Bone OncologyAuthor(s): Alexandros Stamatopoulos, Theodosios Stamatopoulos, Zakareya Gamie, Eustathios Kenanidis, Ricardo Da Conceicao Ribeiro, Kenneth Samora Rankin, Craig Gerrand, Kenneth Dalgarno, Eleftherios TsiridisAbstractOver the past few decades, there has been growing interest in understanding the molecular mechanisms of cancer pathogenesis and progression, as it is still associated with high morbidity and mortality. Current management of large bone sarcomas typically includes the complex therapeutic approach of limb salvage or sacrifice combined w...
Source: Journal of Bone Oncology - March 20, 2019 Category: Cancer & Oncology Source Type: research

Dovitinib dilactic acid reduces tumor growth and tumor-induced bone changes in an experimental breast cancer bone growth model
In this study we used FGFR1 and FGFR2 gene amplifications containing human MFM223 breast cancer cells in an experimental xenograft model of breast cancer bone growth using intratibial inoculation technique. This model mimics bone metastases in breast cancer patients. The effects of an FGFR inhibitor, dovitinib dilactic acid (TKI258) on tumor growth and tumor-induced bone changes were evaluated. Cancer-induced bone lesions were smaller in dovitinib-treated mice as evaluated by X-ray imaging. Peripheral quantitative computed tomography imaging showed higher total and cortical bone mineral content and cortical bone mineral de...
Source: Journal of Bone Oncology - March 20, 2019 Category: Cancer & Oncology Source Type: research

Endoplasmic Reticulum Protein 29 (ERp29) as a Novel Prognostic Marker and Tumor Suppressor in Osteosarcoma
In this study, an expression of ERp29 was examined in patient-derived osteosarcoma cells (7 cases) and normal bone graft-derived osteoblasts (7 cases) using western blotting. Expression profile of ERp29 in 94 osteosarcoma cases was investigated using immunohistochemically stained on formalin-fixed paraffin-embedded biopsied tissue. An association with clinicopathologic parameters and the patient survival was evaluated.Results: The results substantiate the outcome from the proteomic study in which ERp29 expression was significantly higher in primary osteosarcoma cells compared to osteoblastic cells. Immunohistochemical anal...
Source: Journal of Bone Oncology - March 20, 2019 Category: Cancer & Oncology Source Type: research

Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study
Publication date: Available online 7 March 2019Source: Journal of Bone OncologyAuthor(s): Xiaoyi Huang, Jian Zhao, Jinyi Bai, Hua Shen, Bingbing Zhang, Lulu Deng, Chen Sun, Yanfang Liu, Jing Zhang, Jianming ZhengAbstractBackgroundOsteosarcoma is the most common primary sarcoma of the bone. Lung osteosarcoma metastases at diagnosis have a significantly poor prognosis, even when surgery plus chemotherapy are performed. Our goal was to analyze clinical and sarcoma characteristics that could help identify factors related to an increased rate of lung metastasis and to identify different modes of treatment and its correlation wi...
Source: Journal of Bone Oncology - March 9, 2019 Category: Cancer & Oncology Source Type: research

Bone tumours of the clavicle: histopathological, anatomical and epidermiological analysis of 113 cases
Publication date: Available online 6 March 2019Source: Journal of Bone OncologyAuthor(s): Matthias H. Priemel, Norbert Stiel, Jozef Zustin, Andreas M. Luebke, Carsten Schlickewei, Alexander S. SpiroAbstractBackroundThis retrospective study aimed to determine the frequency of bone tumours of the clavicle and their histopathological, anatomical and epidermiological characteristics in a large case series.MethodsThe records of 327 lesions of the clavicle collected from 1976 to 2018 in our bone tumour registry and institute of pathology were reviewed. Following data were evaluated: age, gender, side, radiological assessment, tu...
Source: Journal of Bone Oncology - March 6, 2019 Category: Cancer & Oncology Source Type: research

Long noncoding RNA UCA1 promotes osteosarcoma metastasis through CREB1-mediated epithelial-mesenchymal transition and activating PI3K/AKT/mTOR pathway
In this study, we firstly found UCA1 is upregulated in both osteosarcoma tissues and cell lines, and increased UCA1 is associated with higher tumor stage, larger tumor size and poorer prognosis. Then for the first time, we demonstrated that UCA1 promotes the invasion and metastasis of osteosarcoma both in vitro and in vivo. Further mechanistic investigation showed that UCA1 directly interactes with miR-582 and suppresses its expression. Moreover, UCA1 increases CREB1 expression by functioning as a ceRNA against miR-582, thus promoting the EMT process via CREB1-mediated PI3K/AKT/mTOR pathway and finally leading to osteosarc...
Source: Journal of Bone Oncology - March 1, 2019 Category: Cancer & Oncology Source Type: research

mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model
Publication date: Available online 27 February 2019Source: Journal of Bone OncologyAuthor(s): Chiara Spadazzi, Federica Recine, Laura Mercatali, Giacomo Miserocchi, Chiara Liverani, Alessandro De Vita, Alberto Bongiovanni, Valentina Fausti, Toni IbrahimAbstractThe skeleton is one of the most common sites of metastatic spread from advanced clear-cell renal carcinoma (ccRCC). Most of the bone lesions observed in RCC patients are classified as osteolytic, causing severe pain and morbidity due to pathological bone destruction. Nowadays, it is well known that cancer induced bone loss in lytic metastasis is caused by the trigger...
Source: Journal of Bone Oncology - February 28, 2019 Category: Cancer & Oncology Source Type: research

Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study
Publication date: Available online 19 February 2019Source: Journal of Bone OncologyAuthor(s): C. Wilson, C. Martin, M.C. WinterAbstractBackgroundAdjuvant bisphosphonates (BPs) are recommended as part of routine early breast cancer treatment for many postmenopausal (PM) women within the past year. There is a paucity of ‘real world’ data on compliance and patient satisfaction with oral BPs in this population. The aim of our study was to investigate patient reported compliance and toxicity of these drugs in a retrospective cohort study.Patients and methods413 patient were identified as receiving adjuvant oral BPs ...
Source: Journal of Bone Oncology - February 19, 2019 Category: Cancer & Oncology Source Type: research

Bone transport using the Ilizarov method for osteosarcoma patients with tumor resection and neoadjuvant chemotherapy
ConclusionBone transport using the Ilizarov method can achieve good therapeutic effectiveness in the limb-salvage treatment for OS patients with neoadjuvant chemotherapy as long as the complications can be timely recognized and well managed. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - February 13, 2019 Category: Cancer & Oncology Source Type: research

A Nomogram to Predict Prognosis in Ewing sarcoma of bone
ConclusionOur nomogram is a reliable and powerful tool for distinguishing and predicting the survival of ES patients, thus helping to better select medical examinations and optimize treatment options in collaboration with medical oncologists and surgeons. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - February 13, 2019 Category: Cancer & Oncology Source Type: research

Prediction of survival after surgical management of femoral metastatic bone disease – a comparison of prognostic models
ConclusionsAmong six prognostic models assessed in the setting of femoral metastatic bone disease, the present study observed the most accurate model for 3-month, 6-month, 12-month and 24-month survival. The results of this study may be utilised by the treating surgical team to determine the most accurate model for the required time period and therefore improve decision-making in the care of patients with femoral metastatic bone disease. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - February 13, 2019 Category: Cancer & Oncology Source Type: research

Advances in immune checkpoint inhibitors for bone sarcoma therapy
Publication date: Available online 29 January 2019Source: Journal of Bone OncologyAuthor(s): Pichaya Thanindratarn, Dylan C. Dean, Scott D. Nelson, Francis J. Hornicek, Zhenfeng DuanAbstractBone sarcomas are a collection of sporadic malignancies of mesenchymal origin. The most common subtypes include osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma. Despite the use of aggressive treatment protocols consisting of extensive surgical resection, chemotherapy, and radiotherapy, outcomes have not significantly improved over the past few decades for osteosarcoma or Ewing sarcoma patients. In addition, chondrosarcoma and ...
Source: Journal of Bone Oncology - January 30, 2019 Category: Cancer & Oncology Source Type: research

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
ConclusionsmTOR inhibition leads to a reduction of oxidative and glycolytic metabolism and decreased proliferation in chondrosarcoma cell lines. Although further research is needed, these findings suggest that mTOR inhibition might be a potential therapeutic option for patients with chondrosarcoma. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - January 30, 2019 Category: Cancer & Oncology Source Type: research

Novel 3D-printed prosthetic composite for reconstruction of massive bone defects in lower extremities after malignant tumor resection
ConclusionsPatient-specific 3D-printed prostheses combined with β-TCP bioceramics and/or vascularized fibula provide an excellent option for reconstruction of massive bone defects after lower extremity malignant tumor extirpation. Short-term follow up showed promising clinical results in recovering lower limb function, promoting osseointegration and reducing complications. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - January 25, 2019 Category: Cancer & Oncology Source Type: research

Denosumab Versus Zoledronic Acid in Cases of Surgically Unsalvageable Giant Cell Tumor of Bone: A Randomized Clinical Trial
Publication date: Available online 23 January 2019Source: Journal of Bone OncologyAuthor(s): Shenglong Li, Peng Chen, Qiankun YangAbstractBackgroundAlthough denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven.ObjectivesTo compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with surgically unsalvageable giant cell tumor of bone.MethodsA total of 250 patients with surgically unsalvageable giant cell tumor of bone were included in this randomized clinical trial. Patients received either subcutaneous denosumab (DB group; 120 mg...
Source: Journal of Bone Oncology - January 24, 2019 Category: Cancer & Oncology Source Type: research

Bone metastasis pattern of cancer patients with bone metastasis but no visceral metastasis
ConclusionsIn patients with only one bone containing a metastasis but no visceral metastasis, bones near the primary were more likely to be first metastasized. This may be a valuable clue to primary tumor sites in patients with cancers of unknown primaries. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - January 24, 2019 Category: Cancer & Oncology Source Type: research

Local Control and Vertebral Compression Fractures Following Stereotactic Body Radiotherapy for Spine Metastases
ConclusionsThis study demonstrated that spine SBRT with doses of 16–18 Gy promises good local control of disease with acceptable VCF rates. Lowest vertebral body collapse score, female gender, and>6 months of bisphosphonate use were significantly associated with longer FFS. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - January 24, 2019 Category: Cancer & Oncology Source Type: research

Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data
In this study, a database of oncology electronic health records was linked to administrative claims data. Patients identified were aged ≥18 years and newly diagnosed with MM, had ≥1 clinic visit within 1 month of diagnosis, and ≥1 year of follow-up after diagnosis. The study period was January 1, 2011 to December 31, 2016. 343 patients were included, 35% of whom had a baseline history of any SRE. During a median follow-up of 25.7 months, 34% of patients experienced SREs after diagnosis. Median time to SRE was 167 days. Among patients experiencing an SRE, 68% had an SRE within the first year. The incidence rate of ...
Source: Journal of Bone Oncology - December 26, 2018 Category: Cancer & Oncology Source Type: research

Ewing Sarcoma of the Mobile Spine; Predictive Factors for Survival, Neurological Function and Local Control. A Scandinavian Sarcoma Group Study with a Mean Follow-up of 12 Years
Conclusion: Patients with ES of the mobile have a relatively favorable prognosis. Nonetheless, local recurrence rate is high for this group of patients for which local treatment mainly relies on definitive radiotherapy.Emergency decompressive surgery may increase the risk for local recurrence. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - December 26, 2018 Category: Cancer & Oncology Source Type: research

Allogenic γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma
Publication date: Available online 26 December 2018Source: Journal of Bone OncologyAuthor(s): Yitian Wang, Jian Zhu, Wei Yu, Junjie Wang, Kaishun Xia, Chengzhen Liang, Huimin TaoAbstractHuman γδ T cells have displayed the promising roles in cancer immunity through cytokine secretion and cytotoxic activity. Researches have implicated their principal characteristics as the antigen presentation cells. How to improve γδ T cells' immunotherapeutic effect as the cell vaccine is still a great challenge. Herein, we explore the human γδ T cell and tumor cell fused vaccine for enhanced immunothera...
Source: Journal of Bone Oncology - December 26, 2018 Category: Cancer & Oncology Source Type: research

A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe
ConclusionsAlthough most patients with BMs receive a BTA, there remain a proportion of patients who are not receiving adequate treatment to prevent SREs or manage pain. Oncologists are more likely to adhere to clinical guidelines than urologists for the prescription of BTAs. Bone pain is common and undertreated. Increasing awareness of SRE prevention and bone pain management might improve patient care. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - December 19, 2018 Category: Cancer & Oncology Source Type: research

The need for bone biopsies in the diagnosis of new bone lesions in patients with a known primary malignancy: a comparative review of 117 biopsy cases
CONCLUSIONSThis study has found that 21.4% of newly identified bone lesions in patients with a single known malignancy were not clinically associated with their primary tumor. Furthermore, 3.4% of these were newly discovered malignant bone tumors. The presence of clinical symptoms was identified to be a significant factor affecting whether a new bone lesion was clinically linked to a patient's primary malignancy. It is therefore recommended that active biopsy should be performed on newly found bone lesions of patients with primary malignant tumors, especially on asymptomatic patients or those whose lesions are unidentified...
Source: Journal of Bone Oncology - December 19, 2018 Category: Cancer & Oncology Source Type: research

Managements of Giant Cell Tumor within the Distal Radius: a Retrospective Study of 58 Cases from a Single Center
ConclusionsTaken together, the radiographic presentations (soft-tissue extension and tumor size) are the strong prognostic predictors of local recurrence of GCTB in distal radius. In most tumors, an initial treatment with curettage remains feasible and first-choice, especially with the adjuvant denosumab. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - December 14, 2018 Category: Cancer & Oncology Source Type: research

Surgical options and reconstruction strategies for primary bone tumors of distal tibia: A systematic review of complications and functional outcome
ConclusionsLimb salvage results in better functional outcome compared with amputation. Biological reconstruction is more advocated than prosthetics replacement, and furthermore, autograft might be suggested to be the optimal reconstructive method with regard to better postoperative functional outcome and less major complications. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - December 12, 2018 Category: Cancer & Oncology Source Type: research

Surgical Outcomes of Extracorporeal Irradiation and Re-implantation in Extremities for High Grade Osteosarcoma: A retrospective cohort study and a systematic review of the literature
Publication date: Available online 10 December 2018Source: Journal of Bone OncologyAuthor(s): Dumnoensun Pruksakorn, Jatupon Kongthavonskul, Pimpisa Teeyakasem, Areerak Phanphaisarn, Parunya Chaiyawat, Jeerawan Klangjorhor, Olarn ArpornchayanonAbstractPurposeTo assess the failure rate and mode failure of high-grade osteosarcoma patients who received extracorporeal irradiation and re-implantation (ECIR) in extremities.Patients and MethodsFor the cohort study, patients who had received ECIR at a single institution between January 1996-December 2014 were retrospectively evaluated. Characteristics of failure and time to failur...
Source: Journal of Bone Oncology - December 10, 2018 Category: Cancer & Oncology Source Type: research

Surgical Options and Reconstruction Strategies for Bone Tumors of Distal Tibia: A Systematic Review of Complications and Functional Outcome
ConclusionsLimb salvage results in better functional outcome compared with amputation. Biological reconstruction is more advocated than prosthetics replacement, and furthermore, autograft might be suggested to be the optimal reconstructive method with regard to better postoperative functional outcome and less major complications. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - December 4, 2018 Category: Cancer & Oncology Source Type: research